Charles Moore
Stock Analyst at Robert W. Baird
(3.16)
# 2,511
Out of 4,520 analysts
7
Total ratings
85.7%
Success rate
22.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Moore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintained: Buy | $32 → $34 | $22.73 | +49.58% | 2 | Apr 7, 2026 | |
| CTNM Contineum Therapeutics | Maintained: Buy | $14 → $20 | $14.01 | +42.76% | 2 | Mar 6, 2026 | |
| DRUG Bright Minds Biosciences | Maintained: Buy | $142 → $126 | $74.23 | +69.74% | 3 | Feb 13, 2026 |
Denali Therapeutics
Apr 7, 2026
Maintained: Buy
Price Target: $32 → $34
Current: $22.73
Upside: +49.58%
Contineum Therapeutics
Mar 6, 2026
Maintained: Buy
Price Target: $14 → $20
Current: $14.01
Upside: +42.76%
Bright Minds Biosciences
Feb 13, 2026
Maintained: Buy
Price Target: $142 → $126
Current: $74.23
Upside: +69.74%